Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22814762 | 0.90 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CTSKCA14 | |
| SCHEMBL27162745 | 0.90 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CTSKCA14 | |
| SCHEMBL111602 | 0.83 | CA14 (0.40) | HDAC6HDAC1HDAC2CTSKCA14 | |
| SCHEMBL2622073 | 0.81 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL499275 | 0.81 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CTSKCA14 | |
| SCHEMBL3752709 | 0.79 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CTSKCA14 | |
| SCHEMBL2525841 | 0.79 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL5765810 | 0.79 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CTSKCA14 | |
| SCHEMBL14360869 | 0.78 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14NFKB1 | |
| SCHEMBL7106544 | 0.78 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CTSKCA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655300-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | Epirium Bio Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2024158929-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| US-20240208986-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4329765-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022231927-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20120184482-A1 | Novel Ubiquitin-Isopeptide Probes | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| EP-1501803-B1 | TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROISOQUINOLINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7166614-B2 | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
| US-20060089379-A1 | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2006-04-27 | — | — | US | disclosed |
| US-5723607-A | Compounds useful as antiproliferative agents and GARFT inhibitors | AGOURON PHARMACETICALS, INC. (US) | 1998-03-03 | — | — | US | disclosed |
| EP-0783507-A1 | COMPOUNDS USEFUL AS ANTIPROLIFERATIVE AGENTS AND GARFT INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| US-5641774-A | GLYCINAMIDE RIBONUCLEOTIDE FORMYL TRANSFERASE INHIBITORS; ANTITUMOR AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-24 | — | — | US | disclosed |
| US-5641771-A | FUSED AMIDINE-CONTAINING NITROGEN HETEROCYCLE COMPOUNDS AS ANTITUMOR AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-24 | — | — | US | disclosed |
| US-5639749-A | INHIBITORS OF GLYCINAMIDE RIBONUCLEOTIDE FORMYL TRANSFERASE; ANTITUMOR AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-17 | — | — | US | disclosed |
| US-5639747-A | INHIBITORS OF GLYCINAMIDE RIBONUCLEOTIDE FORMYL TRANSFERASE; ANTITUMOR AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-17 | — | — | US | disclosed |
| US-5625061-A | GRAFT=GLYCINAMIDE RIBONCLEOTIDE FORMYL TRANSFERASE | AGOURON PHARMACEUTICALS, INC. (US) | 1997-04-29 | — | — | US | disclosed |
| US-5610319-A | Compound useful as antiproliferative agents and GARFT inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 1997-03-11 | — | — | US | disclosed |
| US-5594139-A | FROM 5-HAL-2,6-DIAMINO-3H-4-OXOPYRIMIDINE | AGOURON PHARMACEUTICALS, INC. (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996003407-A1 | COMPOUNDS USEFUL AS ANTIPROLIFERATIVE AGENTS AND GARFT INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184482-A1 | Novel Ubiquitin-Isopeptide Probes | USP16, UCHL5, UCHL3 | HDAC6 1077/4885HDAC1 2729/4885HDAC2 3583/4885 |
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | HDAC6 1582/4885HDAC1 1096/4885HDAC2 1711/4885 |
| US-20060089379-A1 | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity | CCR2, CCR5, CCR1 | HDAC6 1869/4885HDAC1 1183/4885HDAC2 1747/4885 |
| US-20240208986-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | RIPK1, RIPK2, RIPK4 | HDAC6 1204/4885HDAC1 818/4885HDAC2 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.